Published in

Taylor and Francis Group, OncoImmunology, 7(3), p. e947892

DOI: 10.4161/21624011.2014.947892

Links

Tools

Export citation

Search in Google Scholar

Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule

Journal article published in 2014 by Gijs G. Zom, Dmitri V. Filippov, Gijsbert A. van der Marel, G. A. van der Marel, Hermen S. Overkleeft ORCID, Cornelis J. Melief, Ferry A. Ossendorp
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Aiming to increase the potency of synthetic long peptide (SLP)-based cancer vaccines, the Toll-like receptor 2 (TLR2) ligand Pam3CSK4 was conjugated in a chemically defined fashion to SLPs harbouring both cytotoxic T lymphocyte (CTL) and T helper epitopes. We recently showed that these SLP-conjugates induce strong antitumor immunity in murine cancer models.